RATIONALE: The mechanisms of airway hyper-responsiveness are only partially understood and the contribution of airway remodelling is unknown. Airway remodelling can be assessed by measuring airway distensibility, which is reduced in asthma, even when lung function is normal. We hypothesised that airway remodelling contributes to airway hyper-responsiveness in asthma, independent of steroid-responsive airway inflammation. OBJECTIVES: To determine the relationship between airway distensibility and airway responsiveness at baseline and after 12 weeks of inhaled corticosteroid therapy in a group of asthmatics with airway hyper-responsiveness. METHODS: Nineteen doctor-diagnosed asthmatics had airway distensibility measured as the slope of the relationship between conductance and lung volume by the forced oscillation technique. Lung function, exhaled nitric oxide and methacholine challenge were also measured. Subjects had inhaled corticosteroid therapy for 12 weeks after which all measurements were repeated. RESULTS: At baseline, airway distensibility (mean, 95%CI) was 0.19(0.14-0.23) cm H(2)O(-1)s(-1), exhaled nitric oxide was 13.1(10.3-16.6)ppb and airway distensibility correlated with eNO (p=0.04) and disease duration (p=0.02) but not with airway responsiveness (p=0.46), FEV(1) (p=0.09) or age (p=0.23). After treatment, exhaled nitric oxide decreased (p=0.0002), FEV(1) improved (p=0.0001), airway responsiveness improved (p=0.0002), and there was a small improvement in airway distensibility but it did not normalise (p=0.05). Airway distensibility was not correlated with either exhaled nitric oxide (p=0.49) or airway responsiveness (p=0.20). CONCLUSIONS: Uncontrolled airway inflammation causes a small decrease in the distensibility of the airways of asthmatics with airway hyper-responsiveness. The lack of association between airway responsiveness and airway distensibility, both before and after 12 weeks ICS treatment, suggests that airway remodelling does not contribute to airway hyper-responsiveness in asthma.
RATIONALE: The mechanisms of airway hyper-responsiveness are only partially understood and the contribution of airway remodelling is unknown. Airway remodelling can be assessed by measuring airway distensibility, which is reduced in asthma, even when lung function is normal. We hypothesised that airway remodelling contributes to airway hyper-responsiveness in asthma, independent of steroid-responsive airway inflammation. OBJECTIVES: To determine the relationship between airway distensibility and airway responsiveness at baseline and after 12 weeks of inhaled corticosteroid therapy in a group of asthmatics with airway hyper-responsiveness. METHODS: Nineteen doctor-diagnosed asthmatics had airway distensibility measured as the slope of the relationship between conductance and lung volume by the forced oscillation technique. Lung function, exhaled nitric oxide and methacholine challenge were also measured. Subjects had inhaled corticosteroid therapy for 12 weeks after which all measurements were repeated. RESULTS: At baseline, airway distensibility (mean, 95%CI) was 0.19(0.14-0.23) cm H(2)O(-1)s(-1), exhaled nitric oxide was 13.1(10.3-16.6)ppb and airway distensibility correlated with eNO (p=0.04) and disease duration (p=0.02) but not with airway responsiveness (p=0.46), FEV(1) (p=0.09) or age (p=0.23). After treatment, exhaled nitric oxide decreased (p=0.0002), FEV(1) improved (p=0.0001), airway responsiveness improved (p=0.0002), and there was a small improvement in airway distensibility but it did not normalise (p=0.05). Airway distensibility was not correlated with either exhaled nitric oxide (p=0.49) or airway responsiveness (p=0.20). CONCLUSIONS: Uncontrolled airway inflammation causes a small decrease in the distensibility of the airways of asthmatics with airway hyper-responsiveness. The lack of association between airway responsiveness and airway distensibility, both before and after 12 weeks ICS treatment, suggests that airway remodelling does not contribute to airway hyper-responsiveness in asthma.
Authors: Ryan J Adam; Katherine B Hisert; Jonathan D Dodd; Brenda Grogan; Janice L Launspach; Janel K Barnes; Charles G Gallagher; Jered P Sieren; Thomas J Gross; Anthony J Fischer; Joseph E Cavanaugh; Eric A Hoffman; Pradeep K Singh; Michael J Welsh; Edward F McKone; David A Stoltz Journal: JCI Insight Date: 2016-04-07
Authors: A C Toledo; C P P Sakoda; A Perini; N M Pinheiro; R M Magalhães; S Grecco; I F L C Tibério; N O Câmara; M A Martins; J H G Lago; C M Prado Journal: Br J Pharmacol Date: 2013-04 Impact factor: 8.739
Authors: C L Fang; L J Yin; S Sharma; S Kierstein; H F Wu; G Eid; A Haczku; C J Corrigan; S Ying Journal: Clin Exp Allergy Date: 2015-05 Impact factor: 5.018
Authors: Samuel Mailhot-Larouche; Mélanie Lachance; Michela Bullone; Cyndi Henry; Ronald J Dandurand; Louis-Philippe Boulet; Michel Laviolette; Gregory G King; Claude S Farah; Ynuk Bossé Journal: Front Physiol Date: 2017-04-12 Impact factor: 4.566
Authors: Katharine C Pike; Shelley A Davis; Samuel A Collins; Jane S A Lucas; Hazel M Inskip; Susan J Wilson; Elin R Thomas; Harris A Wain; Piia H M Keskiväli-Bond; Cyrus Cooper; Keith M Godfrey; Christopher Torrens; Graham Roberts; John W Holloway Journal: Sci Rep Date: 2014-04-17 Impact factor: 4.379
Authors: Martin T Johnson; Ping Xin; J Cory Benson; Trayambak Pathak; Vonn Walter; Scott M Emrich; Ryan E Yoast; Xuexin Zhang; Gaoyuan Cao; Reynold A Panettieri; Mohamed Trebak Journal: Proc Natl Acad Sci U S A Date: 2022-01-04 Impact factor: 11.205